Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have received an average recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $39.36.
A number of brokerages recently commented on RCUS. Leerink Partners increased their price target on Arcus Biosciences from $46.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. JPMorgan Chase & Co. initiated coverage on shares of Arcus Biosciences in a research report on Wednesday, October 14th. They set an “overweight” rating and a $41.00 price objective for the company. Wall Street Zen lowered shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, October 24th. Truist Financial dropped their price objective on shares of Arcus Biosciences from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, November 5th. Finally, TD Cowen assumed coverage on shares of Arcus Biosciences in a report on Wednesday, September 16th. They issued a “buy” rating on the stock.
Read Our Latest Stock Analysis on RCUS
Arcus Biosciences Stock Up 3.4%
RCUS stock opened at $18.90 on Thursday. Arcus Biosciences has a fifty-two week low of $17.43 and a fifty-two week high of $31.74. The business’s 50-day moving average is $23.54 and its two-hundred day moving average is $24.52. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.82 and a current ratio of 3.82. The company has a market cap of $2.41 billion, a price-to-earnings ratio of -5.21 and a beta of 1.04.
Arcus Biosciences (NYSE:RCUS – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.11). Arcus Biosciences had a negative net margin of 453.00% and a negative return on equity of 83.94%. The firm had revenue of $9.00 million for the quarter, compared to the consensus estimate of $7.58 million. During the same quarter in the prior year, the firm earned ($1.27) earnings per share. The company’s revenue for the quarter was down 65.4% compared to the same quarter last year. As a group, analysts forecast that Arcus Biosciences will post -3.57 earnings per share for the current year.
Insider Activity at Arcus Biosciences
In related news, CAO Alexander Azoy sold 2,827 shares of Arcus Biosciences stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the completion of the transaction, the chief accounting officer owned 39,581 shares in the company, valued at approximately $1,187,430. This trade represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.60% of the company’s stock.
Institutional Investors Weigh In On Arcus Biosciences
Institutional investors have recently modified their holdings of the stock. Hantz Financial Services Inc. increased its position in shares of Arcus Biosciences by 47.6% during the third quarter. Hantz Financial Services Inc. now owns 2,937 shares of the company’s stock worth $76,000 after purchasing an additional 947 shares in the last quarter. Diversified Trust Co purchased a new stake in shares of Arcus Biosciences in the third quarter worth about $662,000. Aberdeen Group plc boosted its stake in shares of Arcus Biosciences by 62.4% in the third quarter. Aberdeen Group plc now owns 1,056,679 shares of the company’s stock worth $27,294,000 after buying an additional 405,967 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Arcus Biosciences by 65.0% during the third quarter. Russell Investments Group Ltd. now owns 134,530 shares of the company’s stock worth $3,475,000 after acquiring an additional 52,981 shares during the period. Finally, Maryland State Retirement & Pension System grew its stake in shares of Arcus Biosciences by 58.7% during the 3rd quarter. Maryland State Retirement & Pension System now owns 20,135 shares of the company’s stock worth $520,000 after purchasing an additional 7,449 shares during the period. 92.89% of the stock is owned by institutional investors.
Arcus Biosciences Company Profile
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2015 and headquartered in Hayward, California, the company researches therapies that target immune pathways and other processes involved in tumor growth.
Its pipeline consists of investigational medicines, including antibody and small-molecule candidates designed to be used alone or in combination. Arcus’s research has focused on areas such as checkpoint inhibition and the adenosine pathway; its candidates are under clinical development and are not established treatments.
Arcus works with Gilead Sciences on the development of oncology medicines, extending its work through a major biopharmaceutical collaboration.
Featured Articles
- Five stocks we like better than Arcus Biosciences
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
